User login
Key clinical point: Add-on sublingual immunotherapy (SLIT) with house dust mite (HDM) extract may effectively improve signs and symptoms of atopic dermatitis in patients sensitized to HDM.
Major finding: After 18 months, the SCORing Atopic Dermatitis score decrease in HDM SLIT vs. placebo groups was 55.6% vs. 34.5%, with a significant mean difference of 20.4 (95% credible interval [CI] 3.89-37.3). A significantly higher proportion of patients in the HDM SLIT vs. placebo groups achieved the Investigator’s Global Assessment score of 0/1 (relative risk 2.63; 95% CI, 1.09-6.39). Headache and abdominal pain were the most common adverse events reported by both groups.
Study details: Findings are from a phase 4 study including 91 patients, mostly with moderate-to-severe AD, who were randomly assigned to receive HDM SLIT or placebo for 18 months along with background AD therapy.
Disclosures: This study was funded by the São Paulo Research Foundation, Brazilian National Council for Scientific and Technological Development, and others. Two authors declared receiving doctoral scholarship and research grants from various sources.
Source: Langer SS et al. J Allergy Clin Immunol Pract. 2021 (Nov 9). Doi: 10.1016/j.jaip.2021.10.060.
Key clinical point: Add-on sublingual immunotherapy (SLIT) with house dust mite (HDM) extract may effectively improve signs and symptoms of atopic dermatitis in patients sensitized to HDM.
Major finding: After 18 months, the SCORing Atopic Dermatitis score decrease in HDM SLIT vs. placebo groups was 55.6% vs. 34.5%, with a significant mean difference of 20.4 (95% credible interval [CI] 3.89-37.3). A significantly higher proportion of patients in the HDM SLIT vs. placebo groups achieved the Investigator’s Global Assessment score of 0/1 (relative risk 2.63; 95% CI, 1.09-6.39). Headache and abdominal pain were the most common adverse events reported by both groups.
Study details: Findings are from a phase 4 study including 91 patients, mostly with moderate-to-severe AD, who were randomly assigned to receive HDM SLIT or placebo for 18 months along with background AD therapy.
Disclosures: This study was funded by the São Paulo Research Foundation, Brazilian National Council for Scientific and Technological Development, and others. Two authors declared receiving doctoral scholarship and research grants from various sources.
Source: Langer SS et al. J Allergy Clin Immunol Pract. 2021 (Nov 9). Doi: 10.1016/j.jaip.2021.10.060.
Key clinical point: Add-on sublingual immunotherapy (SLIT) with house dust mite (HDM) extract may effectively improve signs and symptoms of atopic dermatitis in patients sensitized to HDM.
Major finding: After 18 months, the SCORing Atopic Dermatitis score decrease in HDM SLIT vs. placebo groups was 55.6% vs. 34.5%, with a significant mean difference of 20.4 (95% credible interval [CI] 3.89-37.3). A significantly higher proportion of patients in the HDM SLIT vs. placebo groups achieved the Investigator’s Global Assessment score of 0/1 (relative risk 2.63; 95% CI, 1.09-6.39). Headache and abdominal pain were the most common adverse events reported by both groups.
Study details: Findings are from a phase 4 study including 91 patients, mostly with moderate-to-severe AD, who were randomly assigned to receive HDM SLIT or placebo for 18 months along with background AD therapy.
Disclosures: This study was funded by the São Paulo Research Foundation, Brazilian National Council for Scientific and Technological Development, and others. Two authors declared receiving doctoral scholarship and research grants from various sources.
Source: Langer SS et al. J Allergy Clin Immunol Pract. 2021 (Nov 9). Doi: 10.1016/j.jaip.2021.10.060.